Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
Abstract Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget imp...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | BMC Health Services Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12913-022-08683-y |
| _version_ | 1828156118855057408 |
|---|---|
| author | Hyun Kyeong Yoo Han Geul Byun Flavio Caprioli Mathurin Fumery Laurent Peyrin-Biroulet Subramanian Sreedhar James Potter Minyoung Jang |
| author_facet | Hyun Kyeong Yoo Han Geul Byun Flavio Caprioli Mathurin Fumery Laurent Peyrin-Biroulet Subramanian Sreedhar James Potter Minyoung Jang |
| author_sort | Hyun Kyeong Yoo |
| collection | DOAJ |
| description | Abstract Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget impact analysis of introducing infliximab SC to the Big-5 European (E5) market (Germany, France, Italy, Spain and UK) for 5 years, from the healthcare payer’s perspective. Methods A prevalence-based budget impact model was developed to examine the financial impact of infliximab SC. “World with” versus “world without” infliximab SC scenarios were compared, including the potential administration costs of IV administration. Results Introducing infliximab SC in patients with Crohn’s disease (CD) for 5 years resulted in cost savings of €42.0 million in the UK, €59.4 million in Germany, and €46.4 million in France and Italy, but increased budget expenditure in Spain by €3.8 million. For ulcerative colitis (UC), cost savings of €42.7 million in the UK, €44.9 million in Germany, €44.3 million in France, and €53.0 million in Italy occurred, but with no savings in Spain for 5 years. Cost-savings per patient was calculated by diving the net budget saving by number of treatment eligible patients. Maximum and minimum saving per patient per year ranged between €38.25 and €575.74 in CD, both from Germany, and €105.06 (France) and €647.25 (Germany) in UC. Conclusion Healthcare payers in the UK, Germany, France, and Italy, but not in Spain, will make budget savings by using infliximab SC for the treatment of inflammatory bowel disease. |
| first_indexed | 2024-04-11T23:05:18Z |
| format | Article |
| id | doaj.art-4fe833f7f63e4fb99887df81407daaae |
| institution | Directory Open Access Journal |
| issn | 1472-6963 |
| language | English |
| last_indexed | 2024-04-11T23:05:18Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Health Services Research |
| spelling | doaj.art-4fe833f7f63e4fb99887df81407daaae2022-12-22T03:58:01ZengBMCBMC Health Services Research1472-69632022-11-012211910.1186/s12913-022-08683-yBudget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countriesHyun Kyeong Yoo0Han Geul Byun1Flavio Caprioli2Mathurin Fumery3Laurent Peyrin-Biroulet4Subramanian Sreedhar5James Potter6Minyoung Jang7Celltrion HealthcareCelltrion HealthcareDepartment of Pathophysiology and Transplantation, Università Degli Studi Di MilanoService Hépato-Gastroentérologie, CHU Amiens PicardieDepartment of Gastroenterology, Nancy University HospitalDepartment of Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS TrustCelltrion HealthcareCelltrion HealthcareAbstract Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget impact analysis of introducing infliximab SC to the Big-5 European (E5) market (Germany, France, Italy, Spain and UK) for 5 years, from the healthcare payer’s perspective. Methods A prevalence-based budget impact model was developed to examine the financial impact of infliximab SC. “World with” versus “world without” infliximab SC scenarios were compared, including the potential administration costs of IV administration. Results Introducing infliximab SC in patients with Crohn’s disease (CD) for 5 years resulted in cost savings of €42.0 million in the UK, €59.4 million in Germany, and €46.4 million in France and Italy, but increased budget expenditure in Spain by €3.8 million. For ulcerative colitis (UC), cost savings of €42.7 million in the UK, €44.9 million in Germany, €44.3 million in France, and €53.0 million in Italy occurred, but with no savings in Spain for 5 years. Cost-savings per patient was calculated by diving the net budget saving by number of treatment eligible patients. Maximum and minimum saving per patient per year ranged between €38.25 and €575.74 in CD, both from Germany, and €105.06 (France) and €647.25 (Germany) in UC. Conclusion Healthcare payers in the UK, Germany, France, and Italy, but not in Spain, will make budget savings by using infliximab SC for the treatment of inflammatory bowel disease.https://doi.org/10.1186/s12913-022-08683-yInflammatory bowel diseaseUlcerative colitisCrohn’s diseaseBudget impact |
| spellingShingle | Hyun Kyeong Yoo Han Geul Byun Flavio Caprioli Mathurin Fumery Laurent Peyrin-Biroulet Subramanian Sreedhar James Potter Minyoung Jang Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries BMC Health Services Research Inflammatory bowel disease Ulcerative colitis Crohn’s disease Budget impact |
| title | Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries |
| title_full | Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries |
| title_fullStr | Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries |
| title_full_unstemmed | Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries |
| title_short | Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries |
| title_sort | budget impact analysis of the subcutaneous infliximab ct p13 sc for treating inflammatory bowel disease in the big 5 european e5 countries |
| topic | Inflammatory bowel disease Ulcerative colitis Crohn’s disease Budget impact |
| url | https://doi.org/10.1186/s12913-022-08683-y |
| work_keys_str_mv | AT hyunkyeongyoo budgetimpactanalysisofthesubcutaneousinfliximabctp13scfortreatinginflammatoryboweldiseaseinthebig5europeane5countries AT hangeulbyun budgetimpactanalysisofthesubcutaneousinfliximabctp13scfortreatinginflammatoryboweldiseaseinthebig5europeane5countries AT flaviocaprioli budgetimpactanalysisofthesubcutaneousinfliximabctp13scfortreatinginflammatoryboweldiseaseinthebig5europeane5countries AT mathurinfumery budgetimpactanalysisofthesubcutaneousinfliximabctp13scfortreatinginflammatoryboweldiseaseinthebig5europeane5countries AT laurentpeyrinbiroulet budgetimpactanalysisofthesubcutaneousinfliximabctp13scfortreatinginflammatoryboweldiseaseinthebig5europeane5countries AT subramaniansreedhar budgetimpactanalysisofthesubcutaneousinfliximabctp13scfortreatinginflammatoryboweldiseaseinthebig5europeane5countries AT jamespotter budgetimpactanalysisofthesubcutaneousinfliximabctp13scfortreatinginflammatoryboweldiseaseinthebig5europeane5countries AT minyoungjang budgetimpactanalysisofthesubcutaneousinfliximabctp13scfortreatinginflammatoryboweldiseaseinthebig5europeane5countries |